StonvexLoading…
StonvexStonvexStonvexCore line items from NGS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 | Annual 2023 2023-12-31 |
|---|---|---|---|---|
Revenue | $10.07M | $6.74M | $3.17M | $15.01M |
Operating Income | $27.28M | $17.82M | $9.32M | $10.46M |
Net Income | $14.36M | $4.25M | $5.10M | $4.75M |
EPS (Diluted) | $1.15 | $0.75 | $0.41 | $0.38 |
Total Assets | $498.07M | $489.17M | $486.18M | $478.73M |
Total Liabilities | $246.88M | $243.50M | $244.91M | $242.84M |
Cash & Equivalents | $410.00K | $3.62M | $5.24M | $2.75M |
Free Cash Flow OCF − CapEx | $-313.00K | $2.86M | $-5.32M | $-135.91M |
Shares Outstanding | 12.51M | 12.48M | 12.46M | 12.40M |